The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment

Bibliography

• Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965;13:238-52
   PubMed Web of Science ®Google Scholar
• Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 2004;303:1818-22
   PubMed Web of Science ®Google Scholar
• Adler-Moore J. AmBisome targeting to fungal infections. Bone Marrow Transplant 1994;14(Suppl 5):S3-7
   PubMedGoogle Scholar
• Batist G, Ramakrishnan G, Rao CS, Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001;19:1444-54
   PubMed Web of Science ®Google Scholar
• Northfelt DW, Dezube BJ, Thommes JA, Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J Clin Oncol 1997;15:653-9
   PubMed Web of Science ®Google Scholar
• Presant CA, Scolaro M, Kennedy P, Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma. Lancet 1993;341(8855):1242-3
   PubMed Web of Science ®Google Scholar
• Glantz MJ, Jaeckle KA, Chamberlain MC, A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 1999;5:3394-402
   PubMed Web of Science ®Google Scholar
• Zhigaltsev IV, Maurer N, Akhong QF, Liposome-encapsulated vincristine, vinblastine and vinorelbine: a comparative study of drug loading and retention. J Control Release 2005;104(1):103-11
   PubMed Web of Science ®Google Scholar
• Sachetelli S, Beaulac C, Riffon R, Lagace J. Evaluation of the pulmonary and systemic immunogenicity of Fluidosomes, a fluid liposomal-tobramycin formulation for the treatment of chronic infections in lungs. Biochim Biophys Acta 1999;1428(2-3):334-40
   PubMed Web of Science ®Google Scholar
• Sweeney LG, Wang Z, Loebenberg R, Spray-freeze-dried liposomal ciprofloxacin powder for inhaled aerosol drug delivery. Int J Pharm 2005;305(1-2):180-5
   PubMed Web of Science ®Google Scholar
• Pastorino F, Brignole C, Marimpietri D, Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res 2003;63(21):7400-9
   PubMed Web of Science ®Google Scholar
• Lee RJ, Low PS. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta 1995;1233:134-44
   PubMed Web of Science ®Google Scholar
• Suzuki S, Inoue K, Hongoh A, Modulation of doxorubicin resistance in a doxorubicin-resistant human leukaemia cell by an immunoliposome targeting transferrin receptor. Br J Cancer 1997;76(1):83-9
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy; mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res 1986;46(12 Pt 1):6387-92
   PubMed Web of Science ®Google Scholar
• Kong G, Braun RD, Dewhirst MW. Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res 2001;61(7):3027-32
   PubMed Web of Science ®Google Scholar
• Maeda H, Wu J, Sawa T, Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000;65:271-84
   PubMed Web of Science ®Google Scholar
• Sapra P, Tyagi P, Allen TM. Ligand-targeted liposomes for cancer treatment. Curr Drug Deliv 2005;2(4):369-81
   PubMedGoogle Scholar
• Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002;2(10):750-63
   PubMed Web of Science ®Google Scholar
• Park JW, Benz CC, Martin FJ. Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol 2004;31(6 Suppl 13):196-205
   PubMed Web of Science ®Google Scholar
• Kontermann RE. Immunoliposomes for cancer therapy. Curr Opin Mol Ther 2006;8(1):39-45
   PubMed Web of Science ®Google Scholar
• Romberg B, Metselaar JM, Baranyi L, Poly(amino acid)s: promising enzymatically degradable stealth coatings for liposomes. Int J Pharm 2007;331(2):186-9
   PubMedGoogle Scholar
• Papahadjopoulos D, Allen TM, Gabizon A, Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 1991;88(24):11460-4
   PubMed Web of Science ®Google Scholar
• Gabizon A, Catane R, Uziely B, Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994;54:987-92
   PubMed Web of Science ®Google Scholar
• Allen TM, Cheng WW, Hare JI, Laginha KM. Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer. Anticancer Agents Med Chem 2006;6(6):513-23
   PubMedGoogle Scholar
• Charrois GJR, Allen TM. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim Biophys Acta 2004;1663(1-2):167-77
   PubMed Web of Science ®Google Scholar
• Allen TM, Mumbengegwi DR, Charrois GJ. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates. Clin Cancer Res 2005;11:3567-73
   PubMed Web of Science ®Google Scholar
• Johnston MJ, Semple SC, Klimuk SK, Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations. Biochim Biophys Acta 2006;1758(1):55-64
   PubMed Web of Science ®Google Scholar
• Sapra P, Allen TM. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res 2002;62(24):7190-4
   PubMed Web of Science ®Google Scholar
• Kirpotin DB, Drummond DC, Shao Y, Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006;66(13):6732-40
   PubMed Web of Science ®Google Scholar
• Roth A, Drummond DC, Conrad F, Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells. Mol Cancer Ther 2007;6(10):2737-46
   PubMed Web of Science ®Google Scholar
• Pastorino F, Brignole C, Di Paolo D, Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res 2006;66(20):10073-82
   PubMed Web of Science ®Google Scholar
• Pastorino F, Di Paolo D, Piccardi F, Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin. Clin Cancer Res 2008;14(22):7320-9
   PubMed Web of Science ®Google Scholar
• Park JW, Hong K, Kirpotin DB, Anti-HER2 immunoliposomes: Enhanced efficacy attributable to targeted delivery. Clin Cancer Res 2002;8(4):1172-81
   PubMed Web of Science ®Google Scholar
• Roth P, Hammer C, Piguet AC, Effects on hepatocellular carcinoma of doxorubicin-loaded immunoliposomes designed to target the VEGFR-2. J Drug Target 2007;15(9):623-31
   PubMed Web of Science ®Google Scholar
• Sapra P, Allen TM. Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes. Clin Cancer Res 2004;10(7):2530-7
   PubMed Web of Science ®Google Scholar
• Atobe K, Ishida T, Ishida E, In vitro efficacy of a sterically stabilized immunoliposomes targeted to membrane type 1 matrix metalloproteinase (MT1-MMP). Biol Pharm Bull 2007;30(5):972-8
   PubMed Web of Science ®Google Scholar
• Li SD, Huang L. Surface-modified LPD nanoparticles for tumor targeting. Ann NY Acad Sci 2006;1082:1-8
   PubMed Web of Science ®Google Scholar
• Chen H, Ahn R, Van den Bossche J, Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide. Mol Cancer Ther 2009;8(7):1955-63
   PubMed Web of Science ®Google Scholar
• Suzuki R, Takizawa T, Kuwata Y, Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome. Int J Pharm 2008;346(1-2):143-50
   PubMed Web of Science ®Google Scholar
• Emmanouilides C, Jazirehi AR, Bonavida B. Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine. Cancer Biother Radiopharm 2002;17(6):621-30
   PubMed Web of Science ®Google Scholar
• Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 2005;24(13):2121-43
   PubMed Web of Science ®Google Scholar
• Ternant D, Paintaud G. Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin Biol Ther 2005;5(Suppl 1):S37-47
   PubMed Web of Science ®Google Scholar
• Daeron M, Prouvost-Danon A, Voisin GA. Mast cell membrane antigens and Fc receptors in anaphylaxis. II. Functionally distinct receptors for IgG and for IgE on mouse mast cells. Cell Immunol 1980;49(1):178-89
   PubMed Web of Science ®Google Scholar
• Sliwkowski MX, Lofgren JA, Lewis GD, Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999;26(4 Suppl 12):60-70
   PubMed Web of Science ®Google Scholar
• Glennie MJ, van de Winkel JG. Renaissance of cancer therapeutic antibodies. Drug Discov Today 2003;8(11):503-10
   PubMed Web of Science ®Google Scholar
• Thorpe SJ, Turner C, Heath A, Clonal analysis of a human antimouse antibody (HAMA) response. Scand J Immunol 2003;57(1):85-92
   PubMed Web of Science ®Google Scholar
• Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005;23(9):1147-57
   PubMed Web of Science ®Google Scholar
• Qu Z, Griffiths GL, Wegener WA, Development of humanized antibodies as cancer therapeutics. Methods 2005;36(1):84-95
   PubMed Web of Science ®Google Scholar
• Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 1984;81(21):6851-5
   PubMed Web of Science ®Google Scholar
• Jones PT, Dear PH, Foote J, Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986;321(6069):522-5
   PubMed Web of Science ®Google Scholar
• Baskar S, Suschak JM, Samija I, A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display. Blood 2009;114(20):4494-502
   Google Scholar
• Bartelds GM, Wolbink GJ, Stapel S, High levels of human anti-human antibodies to adalimumab in a patient not responding to adalimumab treatment. Ann Rheum Dis 2006;65(9):1249-50
   PubMed Web of Science ®Google Scholar
• de Vries MK, Wolbink GJ, Stapel SO, Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis 2007;66(9):1252-4
   PubMed Web of Science ®Google Scholar
• Bartelds GM, Wijbrandts CA, Nurmohamed MT, Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-TNF naive patients: a cohort study. Ann Rheum Dis 2009 [Epub ahead of print]
   Web of Science ®Google Scholar
• Cheng WW, Allen TM. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv. J Control Release 2008;126(1):50-8
   PubMed Web of Science ®Google Scholar
• Kipriyanov SM, Moldenhauer G, Little M. High level production of soluble single chain antibodies in small-scale Escherichia coli cultures. J Immunol Methods 1997;200(1-2):69-77
   PubMed Web of Science ®Google Scholar
• Houdebine LM. Antibody manufacture in transgenic animals and comparisons with other systems. Curr Opin Biotechnol 2002;13(6):625-9
   PubMed Web of Science ®Google Scholar
• Pini A, Bracci L. Phage display of antibody fragments. Curr Protein Pept Sci 2000;1(2):155-69
   PubMed Web of Science ®Google Scholar
• Lindner P, Bauer K, Krebber A, Specific detection of his-tagged proteins with recombinant anti-His tag scFv-phosphatase or scFv-phage fusions. Biotechniques 1997;22(1):140-9
   PubMed Web of Science ®Google Scholar
• Pavlinkova G, Colcher D, Booth BJ, Effects of humanization and gene shuffling on immunogenicity and antigen binding of anti-TAG-72 single-chain Fvs. Int J Cancer 2001;94:717-26
   PubMed Web of Science ®Google Scholar
• Roque-Navarro L, Mateo C, Lombardero J, Humanization of predicted T-cell epitopes reduces the immunogenicity of chimeric antibodies: new evidence supporting a simple method. Hybrid Hybridomics 2003;22(4):245-57
   PubMedGoogle Scholar
• Sapra P, Moase EH, Ma J, Allen TM. Improved therapeutic responses in a xenograft model of human B-lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragments. Clin Cancer Res 2004;10(3):1100-11
   PubMed Web of Science ®Google Scholar
• Zalipsky S. Synthesis of end-group functionalized polyethylene glycol-lipid conjugates for preparation of polymer-grafted liposomes. Bioconjugate Chem 1993;4:296-9
   PubMed Web of Science ®Google Scholar
• Allen TM, Brandeis E, Hansen CB, A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim Biophys Acta 1995;1237:99-108
   PubMed Web of Science ®Google Scholar
• Kirpotin D, Park JW, Hong K, Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 1997;36:66-75
   PubMed Web of Science ®Google Scholar
• Bendas G, Krause A, Bakowsky U, Targetability of novel immunoliposomes prepared by a new antibody conjugation technique. Int J Pharmaceutics 1999;181(1):79-93
   PubMed Web of Science ®Google Scholar
• Torchilin VP, Levchenko TS, Lukyanov AN, p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. Biochim Biophys Acta 2001;1511:397-411
   PubMed Web of Science ®Google Scholar
• Mamot C, Drummond DC, Greiser U, Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res 2003;63(12):3154-61
   PubMed Web of Science ®Google Scholar
• Pastorino F, Brignole C, Marimpietri D, Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res 2003;63(1):86-92
   PubMed Web of Science ®Google Scholar
• Marty C, Langer-Machova Z, Sigrist S, Isolation and characterization of a scFv antibody specific for tumor endothelial marker 1 (TEM1), a new reagent for targeted tumor therapy. Cancer Lett 2006;235(2):298-308
   PubMed Web of Science ®Google Scholar
• Cheng WW, Das D, Suresh M, Allen TM. Expression and purification of two anti-CD19 single chain Fv fragments for targeting of liposomes to CD19-expressing cells. Biochim Biophys Acta 2007;1768(1):21-9
   PubMed Web of Science ®Google Scholar
• Messerschmidt SK, Kolbe A, Muller D, Novel single-chain Fv' formats for the generation of immunoliposomes by site-directed coupling. Bioconjug Chem 2008;19(1):362-9
   PubMed Web of Science ®Google Scholar
• Lopes de Menezes DE, Pilarski LM, Allen TM. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res 1998;58(15):3320-30
   PubMed Web of Science ®Google Scholar
• Hansen CB, Kao GY, Moase EH, Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim Biophys Acta 1995;1239:133-44
   PubMed Web of Science ®Google Scholar
• Pan X, Lee RJ. Construction of anti-EGFR immunoliposomes via folate-folate binding protein affinity. Int J Pharm 2007;336(2):276-83
   PubMedGoogle Scholar
• Ruger R, Muller D, Fahr A, Kontermann RE. Generation of immunoliposomes using recombinant single-chain Fv fragments bound to Ni-NTA-liposomes. J Drug Target 2005;13(7):399-406
   PubMed Web of Science ®Google Scholar
• Ruger R, Muller D, Fahr A, Kontermann RE. In vitro characterization of binding and stability of single-chain Fv Ni-NTA-liposomes. J Drug Target 2006;14(8):576-82
   PubMed Web of Science ®Google Scholar
• Ishida T, Iden DL, Allen TM. A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs. FEBS Lett 1999;460(1):129-33
   PubMed Web of Science ®Google Scholar
• Iden DL, Allen TM. In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion technique. Biochim Biophys Acta 2001;1513(2):207-16
   PubMed Web of Science ®Google Scholar
• Moreira JN, Ishida T, Gaspar R, Allen TM. Use of the post-insertion technique to insert peptide ligands into pre-formed Stealth liposomes with retention of binding activity and cytotoxicity. Pharm Res 2002;19(3):265-9
   PubMed Web of Science ®Google Scholar
• Nellis DF, Ekstrom DL, Kirpotin DB, Preclinical Manufacture of an Anti-HER2 scFv-PEG-DSPE, Liposome-Inserting conjugate. 1. Gram-Scale Production and Purification. Biotechnol Prog 2005;21(1):205-20
   PubMed Web of Science ®Google Scholar
• Nellis DF, Giardina SL, Janini GM, Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis. Biotechnol Prog 2005;21(1):221-32
   PubMed Web of Science ®Google Scholar
• Lopes de Menezes DE, Pilarski LM, Belch AR, Allen TM. Selective targeting of immunoliposomal doxorubicin against human multiple myeloma in vitro and ex vivo. Biochim Biophys Acta 2000;1466(1-2):205-20
   PubMed Web of Science ®Google Scholar
• Zalipsky S, Hansen CB, Lopes de Menezes DE, Allen TM. Long-circulating polyethylene glycol-grafted immunoliposomes. J Control Release 1996;39:153-61
   Web of Science ®Google Scholar
• Mamot C, Drummond DC, Noble CO, Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res 2005;65(24):11631-8
   PubMed Web of Science ®Google Scholar
• Noble CO, Guo Z, Hayes ME, Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine. Cancer Chemother Pharmacol 2009;64(4):741-51
   PubMed Web of Science ®Google Scholar
• Bendas G, Rothe U, Scherphof GL, Kamps JA. The influence of repeated injections on pharmacokinetics and biodistribution of different types of sterically stabilized immunoliposomes. Biochim Biophys Acta 2003;1609(1):63-70
   PubMed Web of Science ®Google Scholar
• Ishida T, Kiwada H. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int J Pharm 2008;354(1-2):56-62
   PubMedGoogle Scholar
• Wang X, Ishida T, Kiwada H. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J Control Release 2007;119(2):236-44
   PubMed Web of Science ®Google Scholar
• Goren D, Horowitz AT, Zalipsky S, Targeting of Stealth liposomes to erB-2 (Her/2) receptor: in vitro and in vivo studies. Br J Cancer 1996;74:1749-56
   PubMed Web of Science ®Google Scholar
• Houck KS, Huang L. The role of multivalency in antibody mediated liposome targeting. Biochem Biophys Res Commun 1987;145(3):1205-10
   PubMed Web of Science ®Google Scholar
• Maruyama K, Takahashi N, Tagawa T, Immunoliposomes bearing polyethyleneglycol-coupled Fab' fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo. FEBS Lett 1997;413(1):177-80
   PubMed Web of Science ®Google Scholar
• Baum P, Muller D, Ruger R, Kontermann RE. Single-chain Fv immunoliposomes for the targeting of fibroblast activation protein-expressing tumor stromal cells. J Drug Target 2007;15(6):399-406
   PubMed Web of Science ®Google Scholar
• An F, Drummond DC, Wilson S, Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies. Mol Cancer Ther 2008;7(3):569-78
   PubMed Web of Science ®Google Scholar
• Messerschmidt SK, Musyanovych A, Altvater M, Targeted lipid-coated nanoparticles: delivery of tumor necrosis factor-functionalized particles to tumor cells. J Control Release 2009;137(1):69-77
   PubMed Web of Science ®Google Scholar
• Willuda J, Honegger A, Waibel R, High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment. Cancer Res 1999;59(22):5758-67
   PubMed Web of Science ®Google Scholar
• Worn A, Auf der Maur A, Escher D, Correlation between in vitro stability and in vivo performance of anti-GCN4 intrabodies as cytoplasmic inhibitors. J Biol Chem 2000;275(4):2795-803
   PubMed Web of Science ®Google Scholar
• Pedroso I, Irun MP, Machicado C, Sancho J. Four-state equilibrium unfolding of an scFv antibody fragment. Biochemistry 2002;41(31):9873-84
   PubMed Web of Science ®Google Scholar
• Brockmann EC, Cooper M, Stromsten N, Selecting for antibody scFv fragments with improved stability using phage display with denaturation under reducing conditions. J Immunol Methods 2005;296(1-2):159-70
   PubMed Web of Science ®Google Scholar
• Shusta EV, Holler PD, Kieke MC, Directed evolution of a stable scaffold for T-cell receptor engineering. Nat Biotechnol 2000;18(7):754-9
   PubMed Web of Science ®Google Scholar
• Kipriyanov SM, Moldenhauer G, Martin AC, Two amino acid mutations in an anti-human CD3 single chain Fv antibody fragment that affect the yield on bacterial secretion but not the affinity. Protein Eng 1997;10(4):445-53
   PubMedGoogle Scholar
• Worn A, Pluckthun A. Stability engineering of antibody single-chain Fv fragments. J Mol Biol 2001;305(5):989-1010
   PubMed Web of Science ®Google Scholar
• Worn A, Pluckthun A. Different equilibrium stability behavior of ScFv fragments: identification, classification, and improvement by protein engineering. Biochemistry 1999;38(27):8739-50
   PubMed Web of Science ®Google Scholar
• Arndt MA, Krauss J, Rybak SM. Antigen binding and stability properties of non-covalently linked anti-CD22 single-chain Fv dimers. FEBS Lett 2004;578(3):257-61
   PubMed Web of Science ®Google Scholar
• Cheng WW. Targeted delivery of immunoliposomal doxorubicin to B-lymphoid cells via an anti-CD19 whole monoclonal antibody or fragments of antibody. Edmonton: University of Alberta; 2008
   Google Scholar
• Proba K, Honegger A, Pluckthun A. A natural antibody missing a cysteine in VH: consequences for thermodynamic stability and folding. J Mol Biol 1997;265(2):161-72
   PubMed Web of Science ®Google Scholar
• Glockshuber R, Schmidt T, Pluckthun A. The disulfide bonds in antibody variable domains: effects on stability, folding in vitro, and functional expression in Escherichia coli. Biochemistry 1992;31(5):1270-9
   PubMed Web of Science ®Google Scholar
• Proba K, Worn A, Honegger A, Pluckthun A. Antibody scFv fragments without disulfide bonds made by molecular evolution. J Mol Biol 1998;275(2):245-53
   PubMed Web of Science ®Google Scholar
• Worn A, Pluckthun A. An intrinsically stable antibody scFv fragment can tolerate the loss of both disulfide bonds and fold correctly. FEBS Lett 1998;427(3):357-61
   PubMed Web of Science ®Google Scholar
• de Marco A. Strategies for successful recombinant expression of disulfide bond-dependent proteins in Escherichia coli. Microb Cell Fact 2009;8:26-43
   PubMed Web of Science ®Google Scholar
• Reiter Y, Brinkmann U, Webber KO, Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv. Protein Eng 1994;7(5):697-704
   PubMedGoogle Scholar
• Reiter Y, Brinkmann U, Jung SH, Disulfide stabilization of antibody Fv: computer predictions and experimental evaluation. Protein Eng 1995;8(12):1323-31
   PubMedGoogle Scholar
• Robinson CR, Sauer RT. Optimizing the stability of single-chain proteins by linker length and composition mutagenesis. Proc Natl Acad Sci USA 1998;95(11):5929-34
   PubMed Web of Science ®Google Scholar
• Villani ME, Morea V, Consalvi V, Humanization of a highly stable single-chain antibody by structure-based antigen-binding site grafting. Mol Immunol 2008;45(9):2474-85
   PubMed Web of Science ®Google Scholar
• Quintero-Hernandez V, Juarez-Gonzalez VR, Ortiz-Leon M, The change of the scFv into the Fab format improves the stability and in vivo toxin neutralization capacity of recombinant antibodies. Mol Immunol 2007;44(6):1307-15
   PubMed Web of Science ®Google Scholar
• Juarez-Gonzalez VR, Riano-Umbarila L, Quintero-Hernandez V, Directed evolution, phage display and combination of evolved mutants: a strategy to recover the neutralization properties of the scFv version of BCF2 a neutralizing monoclonal antibody specific to scorpion toxin Cn2. J Mol Biol 2005;346(5):1287-97
   PubMed Web of Science ®Google Scholar
• Dona MG, Giorgi C, Accardi L. Characterization of antibodies in single-chain format against the E7 oncoprotein of the human papillomavirus type 16 and their improvement by mutagenesis. BMC Cancer 2007;7:25-38
   PubMedGoogle Scholar
• Kugler M, Stein C, Schwenkert M, Stabilization and humanization of a single-chain Fv antibody fragment specific for human lymphocyte antigen CD19 by designed point mutations and CDR-grafting onto a human framework. Protein Eng Des Sel 2009;22(3):135-47
   PubMed Web of Science ®Google Scholar
• Guisez Y, Demolder J, Mertens N, High-level expression, purification, and renaturation of recombinant murine interleukin-2 from Escherichia coli. Protein Expr Purif 1993;4(3):240-6
   PubMed Web of Science ®Google Scholar
• Seddon AP, Hulmes JD, Decker MM, Refolding and characterization of human recombinant heparin-binding neurite-promoting factor. Protein Expr Purif 1994;5(1):14-21
   PubMed Web of Science ®Google Scholar
• Hoyer M. RK, Pluckthun A. A kinetic trap is an intrinsic feature in the folding pathway of single-chain Fv fragments. Biophys Chem 2002;96(2-3):273-84
   PubMed Web of Science ®Google Scholar
• Francis RJ, Mather SJ, Chester K, Radiolabelling of glycosylated MFE-23:CPG2 fusion protein (MFECP1) with 99mTc for quantitation of tumour antibody-enzyme localisation in antibody-directed enzyme pro-drug therapy (ADEPT). Eur J Nucl Med Mol Imaging 2004;31(8):1090-6
   PubMed Web of Science ®Google Scholar
• Lin Y, Pagel JM, Axworthy D, A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies. Cancer Res 2006;66(7):3884-92
   PubMed Web of Science ®Google Scholar
• Goel A, Beresford GW, Colcher D, Divalent forms of CC49 single-chain antibody constructs in Pichia pastoris: expression, purification, and characterization. J Biochem 2000;127(5):829-36
   PubMed Web of Science ®Google Scholar
• Wittel UA, Jain M, Goel A, The in vivo characteristics of genetically engineered divalent and tetravalent single-chain antibody constructs. Nucl Med Biol 2005;32(2):157-64
   PubMed Web of Science ®Google Scholar
• Das D, Allen TM, Suresh MR. Comparative evaluation of two purification methods of anti-CD19-c-myc-His(6)-Cys scFv. Protein Expr Purif 2005;39(2):199-208
   PubMed Web of Science ®Google Scholar
• Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 2005;23(9):1137-46
   PubMed Web of Science ®Google Scholar
• Mayer A, Francis RJ, Sharma SK, A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug. Clin Cancer Res 2006;12(21):6509-16
   PubMed Web of Science ®Google Scholar
• Bang S, Nagata S, Onda M, HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity. Clin Cancer Res 2005;11(4):1545-50
   PubMed Web of Science ®Google Scholar
• Filpula D, Yang K, Basu A, Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice. Bioconjug Chem 2007;18(3):773-84
   PubMed Web of Science ®Google Scholar
• Laane E, Tani E, Bjorklund E, Flow cytometric immunophenotyping including Bcl-2 detection on fine needle aspirates in the diagnosis of reactive lymphadenopathy and non-Hodgkin's lymphoma. Cytometry B Clin Cytom 2005;64(1):34-42
   PubMedGoogle Scholar
• Laginha K, Mumbengegwi D, Allen T. Liposomes targeted via two different antibodies: assay, B-cell binding and cytotoxicity. Biochim Biophys Acta 2005;1711(1):25-32
   PubMed Web of Science ®Google Scholar
• Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002;29(1 Suppl 2):2-9
   PubMed Web of Science ®Google Scholar
• Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003;22(47):7359-73568
   PubMed Web of Science ®Google Scholar
• Jilani I, O'Brien S, Manshuri T, Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood 2003;102(10):3514-20
   PubMed Web of Science ®Google Scholar
• Wobser M, Voigt H, Eggert AO, Bcl-2 expression in rituximab refractory cutaneous B-cell lymphoma. Br J Cancer 2007;96(10):1540-3
   PubMed Web of Science ®Google Scholar
• Price-Schiavi SA, Jepson S, Li P, Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int J Cancer 2002;99(6):783-91
   PubMed Web of Science ®Google Scholar
• Nagy P, Friedlander E, Tanner M, Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 2005;65(2):473-82
   PubMed Web of Science ®Google Scholar
• Moase EA, Allen TM. Combination targeting of immunoliposomal therapeutics in a murine model of B-Cell lymphoma. 36th Annual Meeting & Exposition of the Controlled Release Society. Copenhagen, Denmark; 2009
   Google Scholar
• Hare JIM, Moase EA, Allen TM. Combined Anti-vasculature and Anti-tumor Targeting in the Treatment of Metastatic Breast Cancer. 36th Annual Meeting & Exposition of the Controlled Release Society. Copenhagen, Denmark; 2009
   Google Scholar
• Abraham SA, McKenzie C, Masin D, In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading. Clin Cancer Res 2004;10(2):728-38
   PubMed Web of Science ®Google Scholar
• Mayer LD, Harasym TO, Tardi PG, Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther 2006;5(7):1854-63
   PubMed Web of Science ®Google Scholar
• Tardi PG, Gallagher RC, Johnstone S, Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Biochim Biophys Acta 2007;1768(3):678-87
   PubMed Web of Science ®Google Scholar
• Caplen NJ, Kinrade E, Sorgi F, In vitro liposome mediated DNA transfection of epithelial cell lines using the cationic liposome Dc Chol/Dope. Gene Ther 1995;2(9):603-13
   PubMed Web of Science ®Google Scholar
• de Lima MC, Simoes S, Pires P, Gene delivery mediated by cationic liposomes: from biophysical aspects to enhancement of transfection. Mol Membr Biol 1999;16(1):103-9
   PubMed Web of Science ®Google Scholar
• Ishida T, Kirchmeier MJ, Moase EH, Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells. Biochim Biophys Acta 2001;1515:144-58
   PubMed Web of Science ®Google Scholar
• Kakudo T, Chaki S, Futaki S, Transferrin-modified liposomes equipped with a pH-sensitive fusogenic peptide: an artificial viral-like delivery system. Biochemistry 2004;43(19):5618-28
   PubMed Web of Science ®Google Scholar
• Kirpotin D, Hong K, Mullah N, Liposomes with detachable polymer coating: destabilization and fusion of dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface-grafted poly(ethylene glycol). FEBS Lett 1996;388:115-8
   PubMed Web of Science ®Google Scholar
• Torchilin VP, Rammohan R, Weissig V, Levchenko TS. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc Natl Acad Sci USA 2001;98(15):8786-91
   PubMed Web of Science ®Google Scholar
• Zhang JX, Zalipsky S, Mullah N, Pharmaco attributes of dioleoylphosphatidylethanolamine/cholesterylhemisuccinate liposomes containing different types of cleavable lipopolymers. Pharmacol Res 2004;49:185-98
   PubMed Web of Science ®Google Scholar
• Boomer JA, Qualls MM, Inerowicz HD, Cytoplasmic delivery of liposomal contents mediated by an acid-labile cholesterol-vinyl ether-PEG conjugate. Bioconjug Chem 2009;20(1):47-59
   PubMed Web of Science ®Google Scholar
• Cao Y, Suresh MR. Bispecific mAb aided liposomal drug delivery. J Drug Target 2000;8(4):257-66
   PubMed Web of Science ®Google Scholar
• Bruenke J, Fischer B, Barbin K, A recombinant bispecific single-chain Fv antibody against HLA class II and FcgammaRIII (CD16) triggers effective lysis of lymphoma cells. Br J Haematol 2004;125(2):167-79
   PubMed Web of Science ®Google Scholar
• Kellner C, Bruenke J, Stieglmaier J, A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells. J Immunother 2008;31(9):871-84
   PubMed Web of Science ®Google Scholar
• Vallera DA, Chen H, Sicheneder AR, Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy. Leuk Res 2009;33(9):1233-42
   PubMed Web of Science ®Google Scholar
• Horn U, Strittmatter W, Krebber A, High volumetric yields of functional dimeric miniantibodies in Escherichia coli, using an optimized expression vector and high-cell-density fermentation under non-limited growth conditions. Appl Microbiol Biotechnol 1996;46(5-6):524-32
   PubMed Web of Science ®Google Scholar
• Hu S, Li L, Qiao J, Codon optimization, expression, and characterization of an internalizing anti-ErbB2 single-chain antibody in Pichia pastoris. Protein Expr Purif 2006;47(1):249-57
   PubMed Web of Science ®Google Scholar
• Kumada Y, Sakan Y, Kajihara H, Efficient production of single-chain Fv antibody possessing rare codon linkers in fed-batch fermentation. J Biosci Bioeng 2009;107(1):73-7
   PubMed Web of Science ®Google Scholar
• Hu X, O'Hara L, White S, Optimisation of production of a domoic acid-binding scFv antibody fragment in Escherichia coli using molecular chaperones and functional immobilisation on a mesoporous silicate support. Protein Expr Purif 2007;52(1):194-201
   PubMed Web of Science ®Google Scholar
• Shaki-Loewenstein S, Zfania R, Hyland S, A universal strategy for stable intracellular antibodies. J Immunol Methods 2005;303(1-2):19-39
   PubMed Web of Science ®Google Scholar
• Jurado P, de Lorenzo V, Fernandez LA. Thioredoxin fusions increase folding of single chain Fv antibodies in the cytoplasm of Escherichia coli: evidence that chaperone activity is the prime effect of thioredoxin. J Mol Biol 2006;357(1):49-61
   PubMed Web of Science ®Google Scholar
• Sonoda H, Kumada Y, Katsuda T, Yamaji H. Functional expression of single-chain Fv antibody in the cytoplasm of Escherichia coli by thioredoxin fusion and co-expression of molecular chaperones. Protein Expr Purif 2009 [Epub ahead of print]
   PubMedGoogle Scholar
• Wall JG, Pluckthun A. The hierarchy of mutations influencing the folding of antibody domains in Escherichia coli. Protein Eng 1999;12(7):605-11
   PubMedGoogle Scholar
• Franklin SE, Mayfield SP. Prospects for molecular farming in the green alga Chlamydomonas. Curr Opin Plant Biol 2004;7(2):159-65
   PubMed Web of Science ®Google Scholar
• Zhang G, Brokx S, Weiner JH. Extracellular accumulation of recombinant proteins fused to the carrier protein YebF in Escherichia coli. Nat Biotechnol 2006;24(1):100-4
   PubMed Web of Science ®Google Scholar